{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000136","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.915976+00:00","generated_at":"2026-05-17T08:37:57.569003+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment","bullets":["80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.","50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.","Two registrational trials for lead compound IMVT-1402 in Graves' disease are enrolling with topline data expected in 2027.","Immunovant will host an investor call on September 3, 2025, at 4:30 p.m. EDT to discuss the data."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000136","json":"https://secwatch.observer/filing/0001764013-25-000136.json","markdown":"https://secwatch.observer/filing/0001764013-25-000136.md","text":"https://secwatch.observer/filing/0001764013-25-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/0001764013-25-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/imvt-20250903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T08:37:57.569003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}